Bortezomib and daratumumab in refractory autoimmune hemolytic anemia

Am J Hematol. 2023 Oct;98(10):E263-E265. doi: 10.1002/ajh.27025. Epub 2023 Jul 7.

Affiliation

¹ Division of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, Minnesota, USA.

PMID: 37417424
DOI: 10.1002/ajh.27025

No abstract available

Publication types

Letter

MeSH terms

Anemia, Hemolytic, Autoimmune* / drug therapy
Antibodies, Monoclonal / therapeutic use
Bortezomib / therapeutic use
Dexamethasone
Humans
Multiple Myeloma* / complications
Multiple Myeloma* / drug therapy

Substances

Bortezomib
daratumumab
Antibodies, Monoclonal
Dexamethasone